Published in Hepatitis Weekly, May 18th, 2009
"The aim of the study was to asses the efficacy and tolerability of fixed dose peginterferon alpha 2a plus ribavirin for the treatment of HCV genotype 4. A prospective open label study was done on 30 middle eastern treatment naive chronic hepatitis C patients. They were treated with 180 mcg of peginterferon alpha 2a subcutaneous weekly plus oral ribavirin of 1200 mg daily if body weight > 75 kg. The treatment was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly